Overview

Body Weight, Aspirin Dose and Pro-resolving Mediators

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:
0

Participant gender:
All

Summary

This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.

Phase:

Phase 4

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

NYU Langone Health

Treatments:

Aspirin

Criteria

Inclusion Criteria:

1. Age between 40 and 70 years

Exclusion Criteria:

1. Anti-platelet medication use in the past 7 days

2. Aspirin intolerance or allergy

3. Known bleeding or clotting disorder

4. Chronic inflammatory or connective tissue disease

5. Immunological deficiency

6. Diabetes mellitus

7. Prior gastric or bariatric surgery

8. Active smoking

9. Platelet count <100,000

10. Use of omega-3 fatty acid supplementation

11. Use of drugs or supplements known to inhibit COX-1/COX-2/lipoxygenases

12. Corticosteroid use

13. Recent initiation or change in dose of statin therapy

14. Pregnancy